← Back to Search

Alkylating agents

Nemtabrutinib for Chronic Lymphocytic Leukemia

Phase 3
Recruiting
Research Sponsored by Merck Sharp & Dohme LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 94 months
Awards & highlights

Study Summary

This trial will compare a new drug (nemtabrutinib) to existing treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma, to see if it can prevent progression of the disease.

Who is the study for?
This trial is for adults with untreated CLL/SLL who don't have TP53 mutations. They must need treatment, be able to take pills, and not have had major surgery recently or active hepatitis. People with other progressing cancers or severe bleeding disorders can't join.Check my eligibility
What is being tested?
The study compares Nemtabrutinib's effectiveness and safety against standard chemoimmunotherapy (FCR/BR) in extending the time patients live without disease progression. Participants will either receive Nemtabrutinib or a combination of chemotherapy drugs plus Rituximab.See study design
What are the potential side effects?
Possible side effects include nausea, fatigue, risk of infection due to low blood cell counts, allergic reactions to infusion drugs like Rituximab, and potential liver toxicity from chemotherapy agents.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 94 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 94 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-Free Survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as Assessed by Blinded Independent Central Review (BICR)
Secondary outcome measures
Duration of Response (DOR) per iwCLL Criteria 2018 as Assessed by BICR
Number of Participants Who Discontinue Study Treatment Due to an AE
Number of Participants Who Experience an Adverse Event (AE)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: NemtabrutinibExperimental Treatment1 Intervention
Administered daily via oral tablet.
Group II: FCR or BRActive Control7 Interventions
Investigator's choice of fludarabine plus cyclophosphamide plus rituximab (FCR) OR bendamustine plus rituximab (BR). Participants will receive either rituximab or specified approved rituximab biosimilar.

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCLead Sponsor
3,908 Previous Clinical Trials
5,066,346 Total Patients Enrolled
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,790 Previous Clinical Trials
8,067,309 Total Patients Enrolled
~200 spots leftby May 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top